{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-010213","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.094955+00:00","generated_at":"2026-05-31T10:25:22.183137+00:00","sec_items":["5.02","5.03","5.07","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ENDRA Life Sciences approves 1:50 reverse stock split, increases authorized shares to 1B, appoints new Head of Finance","bullets":["Senior Director of Finance Irina Pestrikova resigned Aug 7; Richard Jacroux appointed Head of Finance & principal financial officer on Aug 8.","Stockholders approved increase in authorized common shares from 80M to 1B; amendment filed Aug 8.","Board set reverse stock split ratio at 1-for-50, authorized by stockholders (range 1:20 to 1:50).","At Aug 6 annual meeting: all five director nominees elected; say-on-pay, warrant issuance, and auditor ratification passed."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-010213","json":"https://secwatch.observer/filing/0001654954-24-010213.json","markdown":"https://secwatch.observer/filing/0001654954-24-010213.md","text":"https://secwatch.observer/filing/0001654954-24-010213.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424010213/0001654954-24-010213-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424010213/ndra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:25:22.183137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0dc528ca0d","claim":"Richard Jacroux was appointed as Head of Finance at ENDRA Life Sciences Inc..","evidence_excerpt":"On August 8, 2024, the Company’s Board of Directors (the “Board of Directors”) appointed Richard Jacroux as Head of Finance.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424010213/0001654954-24-010213-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Head of Finance"}],"fact_type":"executive_change"},{"claim_id":"2f25939a99","claim":"Irina Pestrikova resigned as Senior Director, Finance at ENDRA Life Sciences Inc..","evidence_excerpt":"On August 5, 2024, Irina Pestrikova notified ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) of her resignation as the Company’s Senior Director, Finance, effective August 7, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424010213/0001654954-24-010213-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Director, Finance"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}